Mutações inativadoras nos genes TAC3 e TACR3, os quais codificam a neurocinina B (NKB) e o seu receptor NK3R, respectivamente, foram descritas em pacientes com hipogonadismo hipogonadotrófico isolado (HHI) normósmico. A partir desse achado, hipotetizamos que mutações ativadoras na NKB e/ou NK3R resultariam na secreção prematura de GnRH e, consequentemente, no desenvolvimento de puberdade precoce dependente de gonadotrofinas (PPDG). Nesse estudo, investigamos a presença de mutações ativadoras e/ou polimorfismos nos genes TAC3 e TACR3 em pacientes com PPDG, bem como mutações inativadoras e/ou polimorfismos nesses genes em pacientes com retardo constitucional do crescimento e desenvolvimento (RCCD), e HHI normósmico. Duzentos e trinta e sete pacientes com distúrbios puberais centrais idiopáticos foram selecionados, sendo 114 com PPDG, 50 com RCCD, e 73 com HHI normósmico. Um grupo de 150 indivíduos que apresentaram desenvolvimento puberal normal foi utilizado como controle. As regiões codificadoras dos genes TAC3 e TACR3 foram amplificadas pela reação em cadeia da polimerase, seguido de purificação enzimática e seqüenciamento automático direto. Análises in silico e in vitro foram realizadas. Um nova variante foi identificada no gene TAC3, p.A63P, em uma paciente do sexo feminino com PPDG, a qual desenvolveu puberdade aos sete anos de idade. Essa variante (p.A63P) está localizada na proneurocinina B, e análises in silico sugeriram que ela não altera sítios constitutivos de splicing e é benigna para a estrutura da proteína. A análise de segregação familiar mostrou que a mãe da paciente, a qual apresentou um desenvolvimento puberal normal, também apresentava a alteração p.A63P em heterozigose, sugerindo que essa variante não desempenha um papel direto no fenótipo de PPDG. Uma nova variante em heterozigose no gene TACR3, p.A449S, foi identificada em uma paciente do sexo feminino com RCCD, que teve início puberal aos treze anos de idade. A análise do grau de conservação da alanina na posição 449 mostrou que esse aminoácido não é conservado entre as diferentes espécies, e análises in silico sugeriram que essa variante não altera os sítios constitutivos de splicing, e é benigna para a estrutura do NK3R. Três novas variantes no NK3R foram identificadas, p.G18D, p.L58L (c.172C>T) e p.W275*, em três pacientes do sexo masculino não relacionados com HHI normósmico. As variantes p.G18D e p.L58L foram identificadas em heterozigose, enquanto que a variante p.W275* foi identificada em heterozigose associada a variante silenciosa p.L58L (c.172C>T), e em homozigose em outro paciente. Análises in silico sugeriram que a variante p.G18D poderia afetar a funcionalidade do NK3R. Estudos in vitro dessa nova variante foram realizados, e mostraram que a mesma não altera a função do NK3R, visto que o aumento na produção de fosfatidil inositol não diferiu significativamente entre o receptor mutado e selvagem. Todas as novas variantes descritas nos genes TAC3 e TACR3 não foram identificadas em 300 alelos controles. Em conclusão, nosso trabalho identificou novas variantes nos genes TAC3 e TACR3 em pacientes brasileiros com distúrbios puberais centrais idiopáticos, e confirmou o envolvimento do complexo NKB/NK3R na etiologia do HHI normósmico / Inactivating mutations of the TAC3 and TACR3 genes, which encode the neurokinin B (NKB) and its receptor, NK3R, respectively, were described in patients with normosmic isolated hypogonadotropic hypogonadism (IHH). Based on these observations, we hypothesized that gain-of-function mutations in the NKB and/or NK3R might be associated with premature activation of GnRH release, leading to gonadotropin-dependent precocious puberty (GDPP). In this study, we investigated the presence of activating mutations and/or polymorphisms in the TAC3 and TACR3 genes in patients with GDPP, and inactivating mutations and/or polymorphisms in these genes in patients with constitutional delay of growth and puberty (CDGP) and normosmic IHH. It was selected 237 patients with idiopathic central pubertal disorders: 114 with GDPP, 50 with CDGP, and 73 with normosmic IHH. Indeed, a group 150 individuals who had puberty at adequate age was used as controls. The coding regions of TAC3 and TACR3 genes were amplified by polymerase chain reaction followed by enzymatic purification and direct automatic sequencing. In silico and in vitro analyses were performed. A new heterozygous variant in the TAC3 gene, p.A63P, was identified in a Brazilian girl with GDPP who had puberty onset at seven years of age. The p.A63P variant was located in the proneurokinin B and in silico analysis suggested that this variant does not alter constitutive splice sites, and it was benign to the protein. The segregation analysis revealed that her mother was heterozygous for the p.A63P variant (who had a normal pubertal development), suggesting that this variant does not play a role in the GDPP phenotype. It was identified a new heterozygous variant, p.A449S, in the TACR3 gene in a Brazilian girl with CDGP, who had puberty onset at thirteen years of age. Conservation degree analysis of alanine at position 449 showed that this amino acid is not a conserved residue among different species. In silico analyses suggested that this new variant does not alter splice sites or affects the structure of NK3R. Indeed, it was identified three new distinct variants in the TACR3 gene, p.G18D, p.L58L (c.172C>T) and p.W275*, in three unrelated males with normosmic IHH. Both p.G18D and p.L58L (c.172C>T) were identified in heterozygous state, and the p.W275* variant was identified in two of these males, since one in homozygous and in another in heterozygous state in association with the silent variant p.L58L (c.172C>T). In silico analyses suggested that p.G18D might be damaging to the NK3R. In vitro studies of this variant (p.G18D) showed that the amount of inositol phosphate (IP) was not significantly different in cells transfected with the p.G18D mutant receptor than in cells transfected with the wild type receptor, indicating that this variant did not alter the function of the neurokinin B receptor. All new variants identified in the TAC3 and TACR3 genes were absent in 300 control alleles. In conclusion, we identified new variants in the TAC3 and TACR3 genes in Brazilian patients with idiopathic central pubertal disorders. We confirm the key role of the NKB/NK3R complex in the etiology of normosmic IHH

INTRODUÇÃO: O diagnóstico diferencial da síndrome de Cushing (SC) ACTH-dependente é um dos maiores desafios da endocrinologia, devido ao comportamento clínico e laboratorial semelhante de alguns tumores carcinóides com a doença de Cushing (DC). Assim, testes dinâmicos de secreção de ACTH e cortisol têm sido utilizados com o objetivo de identificar respostas que sejam preditivas e específicas no diagnóstico diferencial. O padrão dessas respostas é atribuído à superexpressão de receptores; entretanto, poucos estudos foram realizados para comprovar tal associação. O objetivo deste estudo foi verificar se a secreção de ACTH e cortisol em resposta aos testes do CRH humano (hCRH), da desmopressina, e do peptídeo liberador do GH (GHRP-6) é dependente da magnitude de expressão dos seus respectivos receptores (CRHR1, AVPR1B e GHSR-1a) em amostras de tumores de pacientes portadores da SC ACTH-dependente. CASUÍSTICA E MÉTODOS: Entre 2002 e 2004, foram avaliados 22 pacientes (20 com DC e dois com Secreção Ectópica de ACTH [SEA], carcinóide de pulmão e timo), idade mediana de 32 anos (15-54 anos), sendo 18 do sexo feminino e quatro do sexo masculino, provenientes da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da Universidade de São Paulo. Os pacientes foram submetidos aos testes do hCRH (100 µg), desmopressina (10 µg) e GHRP-6 (1 µg/kg) com dosagens de ACTH e cortisol e também de GH no caso do GHRP-6. Vinte e um indivíduos controles, pareados por sexo e idade, foram submetidos ao teste do GHRP-6. Durante o ato operatório, fragmentos de tumor foram coletados para posterior extração do RNA total. O estudo da expressão foi feito por meio de PCR quantitativo em tempo real dos genes CRHR1, AVPR1B e GHSR-1a em relação ao GAPDH. Fragmentos de tecidos normais (hipófise, pulmão e timo) procedentes de necropsias foram utilizados como controles. RESULTADOS: Observamos maior expressão de GHSR-1a nos pacientes responsivos ao GHRP-6, tanto naqueles com DC quanto no paciente com carcinóide pulmonar. Não houve maior expressão dos receptores CRHR1 e AVPR1B nos pacientes com DC responsivos aos respectivos testes, observando-se, no entanto, uma forte associação entre respostas in vivo e a expressão desses receptores nos pacientes com SEA. As concentrações de ACTH e cortisol induzidas pela administração de GHRP-6 foram mais elevadas nos pacientes com DC quando comparados aos controles, havendo, no entanto, superposição entre as respostas. Observamos também elevação dos níveis séricos de GH nos indivíduos controles e, em menor intensidade, nos pacientes com DC. CONCLUSÕES: Houve maior expressão do receptor GHSR-1a em pacientes com SC ACTH-dependente responsivos ao GHRP-6, estabelecendo-se uma relação direta entre a expressão do receptor e a resposta in vivo ao secretagogo, tanto em pacientes com DC quanto nos portadores de SEA. Uma associação entre a expressão dos receptores CRHR1 e AVPR1B com a resposta in vivo aos respectivos secretagogos foi observada nos pacientes com SEA e não nos pacientes com DC. Tendo em vista a resposta ao GHRP-6 em paciente com SEA, limita-se o uso desse peptídeo no diagnóstico diferencial da SC ACTH-dependente. / INTRODUCTION: The differential diagnosis of ACTH-dependent Cushing\'s syndrome (CS) is one of the major challenges in endocrinology, especially in view of the similar clinical and laboratorial behavior between some carcinoid tumors and Cushing\'s disease (CD). Hence, dynamic tests of ACTH and cortisol release have been carried out with the aim to identify predictive and specific responses for this differential diagnosis. The pattern of the responses has been attributed to receptors overexpression, yet few studies have been undertaken to confirm such association. The aim of the present study was to verify whether ACTH and cortisol release in response to human CRH (hCRH), desmopressin, and GH releasing peptide (GHRP-6) depends on the magnitude of expression of their respective receptors (CRHR1, AVPR1B e GHSR-1a) in samples of tumors from patients with ACTH-dependent CS. PATIENTS AND METHODS: Twenty two patients (20 with CD and 2 with Ectopic ACTH Syndrome [EAS], lung and thymus carcinoid tumors) from the Division of Endocrinology and Metabolism of University of Sao Paulo School of Medicine, median age of 32 years (15-54 years), being 18 females and 4 males, were evaluated between 2002 and 2004. The patients were submitted to dynamic tests with hCRH (100 µg), desmopressin (10 µg) and GHRP-6 (1 µg/kg), with measurement of ACTH and cortisol levels, and also of GH in the case of GHRP-6 stimulation. Twenty one age and sex-matched controls were submitted to the GHRP-6 test. During surgery, tumor fragments were collected and subsequently processed for total mRNA extraction. Gene expression of CRHR1, AVPR1B and GHSR-1a relative to GAPDH was quantitated by real-time qPCR. Tissue samples of normal pituitary, lung and thymus from necropsy were used as controls. RESULTS: Greater expression of GHSR-1a was observed in patients responsive to the GHRP-6 test, both in those with CD and in the one with pulmonary carcinoid tumor. No enhanced expression of receptors CRHR1 and AVPR1B was found in CD patients responsive to the respective dynamic tests, yet there was a strong association between the in vivo responses and the expression of those receptors in the two patients with EAS. GHRP-6 -induced ACTH and cortisol release was more marked in patients with CD as compared with control individuals, but there was overlap of the responses. GH stimulation was observed in control individuals and, to a lesser extent, in patients with CD. CONCLUSIONS: There was greater expression of GHSR-1a in patients with ACTH-dependent CS who responded to GHRP-6, establishing a direct association between receptor gene expression and the in vivo response to the secretagogue in both CD patients and those with EAS. An association between expression of CRHR1 and AVPR1B and the in vivo response to the respective secretagogues was found in patients with EAS but not in those with CD. In view of the response to GHRP-6 in a patient with EAS, we considered the use of this peptide in the differential diagnosis of ACTH-dependent CS of limited value.

Background: Lithium augmentation is a first-line strategy for depressed patients resistant to antidepressive therapy, but little is known about patients’ subsequent long-term course or outcome predictors. We investigated long-term outcomes of unipolar depressed patients who had participated in a study on the effects of lithium augmentation on the hypothalamic-pituitary-adrenocortical system using the combined dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test. Methods: Twelve to 28 months (mean 18.6 ± 4.6 months) after lithium augmentation, 23 patients were assessed with a standardized interview, of which 18 patients had complete DEX/CRH test results. Relapse was diagnosed by DSM-IV criteria (Structured Clinical Interview for DSM-IV; SCID I). Results: Only 11 patients (48%) had a favorable follow-up, defined as absence of major depressive episodes during the observation period. Patients with a favorable and an unfavorable course did not differ in clinical or sociodemographic parameters, endocrinological results or continuation of lithium. However, fewer previous depressive episodes tended to correlate (p = 0.09) with a favorable course. Conclusion: Results from studies using the DEX/CRH test to predict relapse in depressed patients treated with antidepressants were not replicated for lithium augmentation. Our finding could reflect the elevation of DEX/CRH results by lithium, independent of clinical course. Limitations of the study are its small sample size, the heterogeneous clinical baseline conditions and the lack of lithium serum levels. The fact that lithium continuation did not predict the course might be related to the difference between the efficacy of lithium in controlled studies and its effectiveness in naturalistic settings. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

No description available.

Introdução: Alterações em genes relacionados com a secreção de GH ou a organogênese hipofisária foram identificadas em pacientes com deficiência de hormônio do crescimento (DGH) congênita. Entretanto, poucos casos de DGH têm sua etiologia esclarecida. O GHRH é um candidato óbvio para explicar a deficiência isolada de GH (DIGH). Na literatura, os estudos de análise do GHRH não conseguiram identificar mutações, porém são antigos e utilizaram uma metodologia com limitações. A maioria dos pacientes com deficiência hipotálamo-hipofisária múltipla (DHHM) apresenta neuroipófise ectópica sugerindo a importância do estudo de genes que atuam no início do desenvolvimento hipofisário, com expressão inclusive no infundíbulo. O GLI2 é um fator de transcrição na sinalização Sonic Hedgehog, envolvido com o início da embriogênese hipofisária, expresso na bolsa de Rathke primordial e no diencéfalo ventral. Previamente, mutações no GLI2 foram encontradas em pacientes com holoprosencefalia, e também alterações hipofisárias. Objetivos: Analisar o GHRH em 151 pacientes com DIGH (42 brasileiros e 109 encaminhados de centros internacionais) e analisar o GLI2 em 180 pacientes brasileiros com DIGH ou DHHM por PCR e sequenciamento automático dos genes; e descrever o fenótipo dos pacientes com mutações identificadas. Resultados: No GHRH foram identificadas seis variantes em heterozigose com previsão benigna pelas análises in silico. A análise do GLI2 identificou três mutações novas em heterozigose com códon de parada prematuro (p.L788fsX794, p.L694fsX722 e p.E380X), e geração de proteínas truncadas, com perda do domínio responsável pela ativação transcricional. A mutação p.L788fsX794 foi identificada numa paciente com baixa estatura, polidactilia, epilepsia e hipoglicemias. Apresentava deficiência de GH, TSH, ACTH, prolactina, LH e FSH. Na investigação familiar foi diagnosticada DIGH em dois tios e DHHM numa prima. Estes familiares, além de sua mãe e outros parentes maternos também apresentaram a mutação e polidactilia. A mutação p.L694fsX722 foi identificada num menino com baixa estatura por deficiência de GH, além de lábio leporino e fenda palatina. Seu pai, embora saudável, também apresentou a mutação. A mutação p.E380X foi identificada numa lactente com retardo no desenvolvimento, hipoglicemias, poliúria e polidipsia. Apresentava deficiência de GH, ACTH, TSH e ADH. Sua mãe aparentemente normal também apresentou a mutação. Todos os pacientes com DGH e mutação no GLI2 apresentaram neuroipófise ectópica (não visualizada na paciente com p.E380X), adenoipófise hipoplásica e ausência de holoprosencefalia na ressonância magnética. Dezoito variantes não-sinônimas também foram identificadas no GLI2 em 24 pacientes. Dezesseis dessas variantes foram consideradas deletérias em pelo menos um programa de predição in silico e dez delas não foram encontradas em população controle. O fenótipo dos pacientes foi predominante de DHHM e com neuroipófise ectópica e sem holoprosencefalia. Variantes silenciosas, intrônicas e polimorfismos foram identificados no GLI2, mas aparentemente sem alteração funcional. Conclusão: Não identificamos mutação no GHRH e se realmente existe mutação neste gene como causa de DGH, deve ser muito rara. Variantes no GLI2 são frequentes (15%), indicando seu importante papel na etiologia da DGH congênita. Além disso, ampliamos o espectro fenotípico dos pacientes com mutações no GLI2, que foi caracterizado por DIGH ou DHHM, inclusive com diabetes insipidus, neuroipófise ectópica (maioria) e ausência de holoprosencefalia. Outras características observadas foram polidactilia, defeito de linha média facial e herança autossômica dominante com penetrância incompleta / Introduction: Alterations in genes related to GH secretion and pituitary organogenesis have been identified in patients with congenital GH deficiency (GHD). However, in only few cases of GHD the etiology has been established. GH-releasing hormone (GHRH) is an obvious candidate to explain isolated GH deficiency (IGHD). Previous reports in the literature did not identify mutations in GHRH, however, the methodology used was limited. Most patients with combined pituitary hormone deficiency (CPHD) have an ectopic posterior pituitary lobe (EPP) suggesting the study of genes involved in early pituitary development and also expressed in the infundibulum. GLI2 is a transcription factor in Sonic hedgehog signaling expressed in the primordial Rathkes pouch and ventral diencephalon during early pituitary development. Previously, GLI2 mutations were found in patients with holoprosencephaly and pituitary abnormalities. Aim: Analyse GHRH in 151 patients with IGHD (42 Brazilian and 101 from international centers) and GLI2 in 180 Brazilian patients with IGHD or CPHD by PCR and automatic sequencing, and describe the phenotype of patients with mutations. Results: In GHRH, six heterozygous variants that are benign according to in silico analysis were identified. GLI2 study revealed three novel heterozygous mutations leading to premature stop codons (p.L788fsX794, p.L694fsX722 e p.E380X) and truncated proteins, without the transcriptional activator domain. p.L788fsX794 was identified in a girl with short stature, polydactyly, epilepsy and hypoglycemia. She had GH, TSH, ACTH, prolactina, LH and FSH deficiencies. Two uncles had IGHD and one cousin CPHD. These relatives, the mother and other maternal relatives had polydactyly and carried the mutation. p.L694fsX722 was identified in a boy with short stature due to GHD who also had cleft lip and palate. His healthy father also carried the mutation. p.E380X was identified in an infant with delayed development, hypoglycemia, polyuria and polydipsia. She had GH, ACTH, TSH and ADH deficiencies. Her apparently normal mother also carried the mutation. All patients with GHD and GLI2 mutations had an EPP (not visualized in the patient with p.E380X), hypoplastic anterior pituitary lobe and absence of holoprosencephaly on MRI. Eighteen non-synonymous variants in GLI2 were identified in 24 patients. Sixteen of these were considered deleterious in at least one in silico prediction program and ten of these were not found in the control population. The phenotype was mainly of CPHD and EPP without holoprosencephaly. Several synonymous and intronic GLI2 variants and polymorphisms apparently without functional consequences were identified. Conclusions: No mutations in GHRH were identified and if mutations in this gene exist as a cause of IGHD, they must be very rare. Variants in GLI2 are frequent (15%) indicating its important role in the etiology of GHD. Furthermore, we expanded the clinical spectrum of patients with GLI2 mutations characterized by IGHD or CPHD including diabetes insipidus, ectopic posterior pituitary lobe (in most patients) and absence of holoprosencephaly. Additional features were polydactyly and midline facial defects and the inheritance was autosomal dominant with incomplete penetrance

Endocrine and Metabolic Aspects of Various Sleep Disorders MUDr. Zuzana Vimmerová Lattová Abstract: Recent epidemiological and experimental data suggest a negative influence of shortened or disturbed night sleep on glucose tolerance. However, no comparative studies of glucose metabolism have been conducted in clinical sleep disorders. Dysfunction of the HPA axis may play a causative role in some sleep disorders and in other sleep disorders it may be secondary to the sleep disorder. Moreover, dysfunction of the HPA axis is regarded as a possible causative factor for the impaired glucose sensitivity associated with disturbed sleep. However, data on HPA system activity in sleep disorders are sparse and conflicting. We studied 25 obstructive sleep apnea (OSA) patients, 18 restless legs syndrome (RLS) patients, 21 patients with primary insomnia and compared them to 33 healthy controls. We performed oral glucose tolerance test and assessed additional parameters of glucose metabolism. The dynamic response of the HPA system was assessed by the DEX-CRH-test which combines suppression (dexamethasone) and stimulation (CRH) of the stress hormone system. Compared to controls, increased rates of impaired glucose tolerance were found in OSA (OR: 4.9) and RLS (OR: 4.7), but not in primary insomnia. In addition, HbA1c...

Introdução: Alterações em genes relacionados com a secreção de GH ou a organogênese hipofisária foram identificadas em pacientes com deficiência de hormônio do crescimento (DGH) congênita. Entretanto, poucos casos de DGH têm sua etiologia esclarecida. O GHRH é um candidato óbvio para explicar a deficiência isolada de GH (DIGH). Na literatura, os estudos de análise do GHRH não conseguiram identificar mutações, porém são antigos e utilizaram uma metodologia com limitações. A maioria dos pacientes com deficiência hipotálamo-hipofisária múltipla (DHHM) apresenta neuroipófise ectópica sugerindo a importância do estudo de genes que atuam no início do desenvolvimento hipofisário, com expressão inclusive no infundíbulo. O GLI2 é um fator de transcrição na sinalização Sonic Hedgehog, envolvido com o início da embriogênese hipofisária, expresso na bolsa de Rathke primordial e no diencéfalo ventral. Previamente, mutações no GLI2 foram encontradas em pacientes com holoprosencefalia, e também alterações hipofisárias. Objetivos: Analisar o GHRH em 151 pacientes com DIGH (42 brasileiros e 109 encaminhados de centros internacionais) e analisar o GLI2 em 180 pacientes brasileiros com DIGH ou DHHM por PCR e sequenciamento automático dos genes; e descrever o fenótipo dos pacientes com mutações identificadas. Resultados: No GHRH foram identificadas seis variantes em heterozigose com previsão benigna pelas análises in silico. A análise do GLI2 identificou três mutações novas em heterozigose com códon de parada prematuro (p.L788fsX794, p.L694fsX722 e p.E380X), e geração de proteínas truncadas, com perda do domínio responsável pela ativação transcricional. A mutação p.L788fsX794 foi identificada numa paciente com baixa estatura, polidactilia, epilepsia e hipoglicemias. Apresentava deficiência de GH, TSH, ACTH, prolactina, LH e FSH. Na investigação familiar foi diagnosticada DIGH em dois tios e DHHM numa prima. Estes familiares, além de sua mãe e outros parentes maternos também apresentaram a mutação e polidactilia. A mutação p.L694fsX722 foi identificada num menino com baixa estatura por deficiência de GH, além de lábio leporino e fenda palatina. Seu pai, embora saudável, também apresentou a mutação. A mutação p.E380X foi identificada numa lactente com retardo no desenvolvimento, hipoglicemias, poliúria e polidipsia. Apresentava deficiência de GH, ACTH, TSH e ADH. Sua mãe aparentemente normal também apresentou a mutação. Todos os pacientes com DGH e mutação no GLI2 apresentaram neuroipófise ectópica (não visualizada na paciente com p.E380X), adenoipófise hipoplásica e ausência de holoprosencefalia na ressonância magnética. Dezoito variantes não-sinônimas também foram identificadas no GLI2 em 24 pacientes. Dezesseis dessas variantes foram consideradas deletérias em pelo menos um programa de predição in silico e dez delas não foram encontradas em população controle. O fenótipo dos pacientes foi predominante de DHHM e com neuroipófise ectópica e sem holoprosencefalia. Variantes silenciosas, intrônicas e polimorfismos foram identificados no GLI2, mas aparentemente sem alteração funcional. Conclusão: Não identificamos mutação no GHRH e se realmente existe mutação neste gene como causa de DGH, deve ser muito rara. Variantes no GLI2 são frequentes (15%), indicando seu importante papel na etiologia da DGH congênita. Além disso, ampliamos o espectro fenotípico dos pacientes com mutações no GLI2, que foi caracterizado por DIGH ou DHHM, inclusive com diabetes insipidus, neuroipófise ectópica (maioria) e ausência de holoprosencefalia. Outras características observadas foram polidactilia, defeito de linha média facial e herança autossômica dominante com penetrância incompleta / Introduction: Alterations in genes related to GH secretion and pituitary organogenesis have been identified in patients with congenital GH deficiency (GHD). However, in only few cases of GHD the etiology has been established. GH-releasing hormone (GHRH) is an obvious candidate to explain isolated GH deficiency (IGHD). Previous reports in the literature did not identify mutations in GHRH, however, the methodology used was limited. Most patients with combined pituitary hormone deficiency (CPHD) have an ectopic posterior pituitary lobe (EPP) suggesting the study of genes involved in early pituitary development and also expressed in the infundibulum. GLI2 is a transcription factor in Sonic hedgehog signaling expressed in the primordial Rathkes pouch and ventral diencephalon during early pituitary development. Previously, GLI2 mutations were found in patients with holoprosencephaly and pituitary abnormalities. Aim: Analyse GHRH in 151 patients with IGHD (42 Brazilian and 101 from international centers) and GLI2 in 180 Brazilian patients with IGHD or CPHD by PCR and automatic sequencing, and describe the phenotype of patients with mutations. Results: In GHRH, six heterozygous variants that are benign according to in silico analysis were identified. GLI2 study revealed three novel heterozygous mutations leading to premature stop codons (p.L788fsX794, p.L694fsX722 e p.E380X) and truncated proteins, without the transcriptional activator domain. p.L788fsX794 was identified in a girl with short stature, polydactyly, epilepsy and hypoglycemia. She had GH, TSH, ACTH, prolactina, LH and FSH deficiencies. Two uncles had IGHD and one cousin CPHD. These relatives, the mother and other maternal relatives had polydactyly and carried the mutation. p.L694fsX722 was identified in a boy with short stature due to GHD who also had cleft lip and palate. His healthy father also carried the mutation. p.E380X was identified in an infant with delayed development, hypoglycemia, polyuria and polydipsia. She had GH, ACTH, TSH and ADH deficiencies. Her apparently normal mother also carried the mutation. All patients with GHD and GLI2 mutations had an EPP (not visualized in the patient with p.E380X), hypoplastic anterior pituitary lobe and absence of holoprosencephaly on MRI. Eighteen non-synonymous variants in GLI2 were identified in 24 patients. Sixteen of these were considered deleterious in at least one in silico prediction program and ten of these were not found in the control population. The phenotype was mainly of CPHD and EPP without holoprosencephaly. Several synonymous and intronic GLI2 variants and polymorphisms apparently without functional consequences were identified. Conclusions: No mutations in GHRH were identified and if mutations in this gene exist as a cause of IGHD, they must be very rare. Variants in GLI2 are frequent (15%) indicating its important role in the etiology of GHD. Furthermore, we expanded the clinical spectrum of patients with GLI2 mutations characterized by IGHD or CPHD including diabetes insipidus, ectopic posterior pituitary lobe (in most patients) and absence of holoprosencephaly. Additional features were polydactyly and midline facial defects and the inheritance was autosomal dominant with incomplete penetrance

Le récepteur du facteur de libération de l’hormone de croissance (GHRHR) est un récepteur de la famille des récepteurs couplés aux protéines G. Il est fortement exprimé dans les cellules somatotropes de l’hypophyse antérieure de plusieurs mammifères. Ce récepteur exerce un rôle primordial dans la stimulation de la synthèse et de la sécrétion de l’hormone de croissance ainsi que dans la prolifération des somatotropes. Au niveau extrahypophysaire, les niveaux les plus élevés d’ARNm du GHRHR se retrouvent dans le rein. Toutefois, aucune analyse immunohistochimique n’existe encore sur la localisation précise et la quantification sur les niveaux de GHRHR dans les différents segments du rein de rat et sa dynamique d’expression en situation normale et pathologique telle que l’ischémie. De plus, dans le rein humain normal, aucune information n’est présentement disponible. Le premier article de ce mémoire a pour objectif d’identifier, par immunofluorescence directe, la localisation du GHRHR à travers le système tubulaire rénal, chez le rat jeune en bonne santé. Nos résultats mettent en évidence que dans le rein de rat sain, le GHRHR est exprimé dans les cellules du tubule proximal contourné et droit, de l’anse de Henlé ascendante épaisse corticale et médullaire et de l’anse de Henlé ascendante mince. Le cortex et la bande externe de la médulla externe seraient les deux régions où l’expression est la plus élevée. À la suite d’une insulte rénale comme l’ischémie-reperfusion (IR) chaude, nos résultats démontrent que l’expression du GHRHR est régulée à la baisse dans ces mêmes régions. De plus, une augmentation de certains marqueurs de détérioration cellulaire est présente comme l’enzyme initiatrice, la caspase-9 clivée et effectrice (caspase-3 clivée), des fragments d’ADN et la surexpression d’indication d’injure tissulaire comme la protéine Kidney Injury Molecule 1 (KIM-1). L’ensemble de ces résultats ouvre plusieurs pistes d’études concernant l’importance du GHRHR en rénoprotection. Le deuxième article de ce mémoire a pour objectif d’identifier, par immunofluorescence directe, la localisation du GHRHR à travers le système tubulaire rénal humain. Nos résultats suggèrent que dans le rein humain sain, le GHRHR est davantage exprimé dans le cortex, plus précisément, au niveau du tubule proximal droit et contourné et l’anse de Henlé corticale ascendante épaisse. L’expression du GHRHR est aussi notable au niveau de la région médullaire, pour être plus spécifique, au niveau de l’anse de Henlé médullaire ascendante épaisse et de la médulla. Ainsi, comme chez le rat, l’expression du GHRHR rénal est régio-spécifique. Finalement, le troisième article de ce mémoire est une revue de la littérature ayant pour but d’établir un lien entre les mécanismes connus du stress oxydant dans un contexte d’IR rénale et son impact spécifique dans la médulla. Cet article met en évidence que les différents segments du rein réagissent différemment à une agression oxydante et que la médulla est la région la plus vulnérable. De plus, cette revue de la littérature souligne que les différents types de mécanismes connus du stress oxydant dans un contexte d’IR rénale, tel que la production de dérivés réactifs de l’oxygène, ciblent principalement deux structures du néphron : le tubule proximal et l’anse de Henlé ascendante épaisse médullaire. Les principales répercussions de ces mécanismes observables sont l’inflammation, l’apoptose cellulaire et la diminution des fonctions rénales. Ces mécanismes peuvent aussi être utilisés comme un outil de diagnostic ou de détermination de la santé de l’organe. / The growth hormone-releasing factor receptor (GHRHR) is a receptor of the family of G- protein-coupled receptors. It is highly expressed in the somatotropic cells of the anterior pituitary of several mammals. This receptor plays an essential role in the stimulation of the synthesis and secretion of growth hormone as well as in the proliferation of somatotrophs. At the extra- pituitary level, the highest levels of GHRHR mRNA are found in the kidney. However, no immunohistochemical analysis yet exists on precise localization and quantification of GHRHR levels in the different segments of the rat kidney and its expression dynamics in normal and pathological situations such as ischemia. Additionally, in the normal human kidney, no information is currently available. The first article of this thesis aims to identify, by direct immunofluorescence, the localization of the GHRHR through the renal tubular system, in young healthy rats. Our results show that in the healthy rat kidney, GHRHR is expressed in the cells of the convoluted and right proximal tubule, of the cortical and medullary thick ascending loop of Henle and of the thin ascending loop of Henle. The cortex and the outer band of the outer medulla would be the two regions where the expression is the highest. Following a renal insult such as warm ischemia-reperfusion (RI), our results demonstrate that GHRHR expression is down-regulated in these same regions. In addition, an increase in certain markers of cellular damage is present including initiating enzymes, cleaved and effector caspase-9 (cleaved caspase-3), DNA fragments and overexpression indicative of tissue injury such as protein Kidney Injury Molecule 1 (KIM-1). All these results open up several avenues of study concerning the importance of GHRHR in renoprotection. The second article of this thesis aims to identify, by direct immunofluorescence, the localization of the GHRHR through the human renal tubular system. Our results suggest that in the healthy human kidney, the GHRHR is more expressed in the cortex, more precisely at the level of the right, convoluted proximal tubule and the thick ascending cortical loop of Henle. The expression of GHRHR is also appreciable at the level of the medullary region, more precisely at the level of the thick ascending medullary loop of Henle, and the medulla. Thus, as in rats, the expression of renal GHRHR is region specific. Finally, the third article of this thesis is a review of the literature aimed at establishing a link between the known mechanisms of oxidative stress in the context of renal IR and its specific impact in the medulla. This article highlights that the different segments of the kidney react differently to an oxidative attack and that the medulla is the most vulnerable region. In addition, this review of the literature underlines that the different types of known mechanisms of oxidative stress in a context of renal IR, such as the production of reactive oxygen species, mainly target two structures of the nephron: the proximal tubule and the thick ascending loop of Henle. The main repercussions of these observable mechanisms are inflammation, cellular apoptosis and reduced renal function. These mechanisms can also be used as a diagnostic tool or to determine the health of the organ.

Die vorliegende Arbeit beschäftigt sich mit der Untersuchung und Beschreibung der Eigenschaften der synthetischen Dekapeptide Cetrorelix und Ozarelix durch analytische Methoden und computergestützte Modellierung. Diese Moleküle sind hydrophobe, aggregierende Antagonisten des Gonadotropin-Releasing-Hormons (GnRH). Zusätzlich wurden amyloidbildende Peptidstrukturen als Modelle für die Assoziationsprozesse in hydrophoben Peptiden untersucht und visualisiert. Die intrinsische Fluoreszenz der GnRH-Antagonisten und zusätzlich der Peptide Teverelix und D-Phe6-GnRH sowie von verkürzten Fragmenten des Cetrorelix wurde untersucht. Ein Strukturmodell für die Beschreibung der Aggregation der Dekapeptide wurde erarbeitet. Der Aufbau eines Rechenclusters durch das Einbinden der Computer am Lehrstuhl in ein Linux-System zur Verteilung von Rechenprozessen über das Netzwerk ermöglichte die Bereitstellung der notwendigen Leistung zur Realisierung der Berechnungen. Es wurden Werkzeuge zur Modellierung der solvatisierten Aggregate von Peptiden ohne eindeutige Vorzugsstruktur programmiert und in ein Docking-System für beliebige Moleküle eingebunden. Verwendet wurde das Kraftfeld MMFF94 mit einer Erweiterung durch ein Verfahren zur dynamischen Berechnung von Partialladungen in Molekülstrukturen. Solvatisierte Aggregate der Dekapeptide und von bekannten amyloidbildenden Strukturen wurden modelliert (Docking). Berechnet wurden als aggregierend beschriebene Sequenzen und entsprechende Vergleichsstrukturen des Calcitonins, des Insel-Amyloid-Polypeptides, des beta2-Mikroglobulins, des Amyloid-beta-Proteins, des Lactoferrins und weitere Modellpeptide. Die wesentlichen Wechselwirkungen während der Aggregation konnten schließlich anhand von Dynamik-Simulationen der faltblattartigen Dimere des Cetrorelix und Ozarelix beschrieben werden. So wurden die Prozesse der hydrophoben Assoziation und Stabilisierung durch Wasserstoffbrücken von Peptiden veranschaulicht und auf molekularer Ebene erfolgreich analysiert. Die Visualisierung der erhaltenen Modellierungsergebnisse erfolgt durch die Darstellung der Strukturen und Dynamik-Simulationen als interaktive 3D-Modelle in einem für diese Arbeit aufgebauten Internetauftritt. / This work discusses the analysis of the aggregation properties of the gonadotropin releasing hormone antagonists Cetrorelix, Teverelix, Ozarelix and of small amyloid forming model peptides by analytical fluorescence spectroscopy and molecular modelling. A high performance linux compute cluster was developed for calculation of molecular structures. Solvated aggregate clusters of peptides without defined secondary structure were modelled by molecular mechanics methods (forcefield mmff94) in combination with an advanced charge equilibration and docking technique. Molecular dynamics of solvated peptide dimers were implemented and the role of hydrophic association and hydrogen bond formation in hydrophobic peptide aggregates was explained. Finally, an aggregation model for the directed association of hydrophobic peptides is presented. The modelling results, 3d structures and dynamic simulations are visualized in an interactive web material.

Die vorliegende Arbeit beschäftigt sich mit der Untersuchung und Beschreibung der Eigenschaften der synthetischen Dekapeptide Cetrorelix und Ozarelix durch analytische Methoden und computergestützte Modellierung. Diese Moleküle sind hydrophobe, aggregierende Antagonisten des Gonadotropin-Releasing-Hormons (GnRH). Zusätzlich wurden amyloidbildende Peptidstrukturen als Modelle für die Assoziationsprozesse in hydrophoben Peptiden untersucht und visualisiert. Die intrinsische Fluoreszenz der GnRH-Antagonisten und zusätzlich der Peptide Teverelix und D-Phe6-GnRH sowie von verkürzten Fragmenten des Cetrorelix wurde untersucht. Ein Strukturmodell für die Beschreibung der Aggregation der Dekapeptide wurde erarbeitet. Der Aufbau eines Rechenclusters durch das Einbinden der Computer am Lehrstuhl in ein Linux-System zur Verteilung von Rechenprozessen über das Netzwerk ermöglichte die Bereitstellung der notwendigen Leistung zur Realisierung der Berechnungen. Es wurden Werkzeuge zur Modellierung der solvatisierten Aggregate von Peptiden ohne eindeutige Vorzugsstruktur programmiert und in ein Docking-System für beliebige Moleküle eingebunden. Verwendet wurde das Kraftfeld MMFF94 mit einer Erweiterung durch ein Verfahren zur dynamischen Berechnung von Partialladungen in Molekülstrukturen. Solvatisierte Aggregate der Dekapeptide und von bekannten amyloidbildenden Strukturen wurden modelliert (Docking). Berechnet wurden als aggregierend beschriebene Sequenzen und entsprechende Vergleichsstrukturen des Calcitonins, des Insel-Amyloid-Polypeptides, des beta2-Mikroglobulins, des Amyloid-beta-Proteins, des Lactoferrins und weitere Modellpeptide. Die wesentlichen Wechselwirkungen während der Aggregation konnten schließlich anhand von Dynamik-Simulationen der faltblattartigen Dimere des Cetrorelix und Ozarelix beschrieben werden. So wurden die Prozesse der hydrophoben Assoziation und Stabilisierung durch Wasserstoffbrücken von Peptiden veranschaulicht und auf molekularer Ebene erfolgreich analysiert. Die Visualisierung der erhaltenen Modellierungsergebnisse erfolgt durch die Darstellung der Strukturen und Dynamik-Simulationen als interaktive 3D-Modelle in einem für diese Arbeit aufgebauten Internetauftritt. / This work discusses the analysis of the aggregation properties of the gonadotropin releasing hormone antagonists Cetrorelix, Teverelix, Ozarelix and of small amyloid forming model peptides by analytical fluorescence spectroscopy and molecular modelling. A high performance linux compute cluster was developed for calculation of molecular structures. Solvated aggregate clusters of peptides without defined secondary structure were modelled by molecular mechanics methods (forcefield mmff94) in combination with an advanced charge equilibration and docking technique. Molecular dynamics of solvated peptide dimers were implemented and the role of hydrophic association and hydrogen bond formation in hydrophobic peptide aggregates was explained. Finally, an aggregation model for the directed association of hydrophobic peptides is presented. The modelling results, 3d structures and dynamic simulations are visualized in an interactive web material.